A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091

NCT05128591 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Embolism and Thrombosis

Interventions

DRUG: Rivaroxaban 18mg Oral Tablet
DRUG: Rivaroxaban 20 MG Oral Tablet

Sponsor

Addpharma Inc.